Differential effects of urapidil and doxazosin on heart rate

European Journal of Clinical Pharmacology

Volumn 63, Issue 3, 2007, Pages 259-262

  Stoschitzky, Kurt ^a,b   Stoschitzky, Gergana ^a   Wonisch, Manfred ^a   Brussee, Helmut ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Adrenergic alpha antagonists; Blood pressure; Heart rate; Hypertension; Rate pressure product

Indexed keywords

DOXAZOSIN; PLACEBO; URAPIDIL;

ADULT; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EXERCISE; HEART RATE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE;

ADRENERGIC ALPHA-ANTAGONISTS; ADULT; BLOOD PRESSURE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DOXAZOSIN; HEART RATE; HUMANS; MALE; PIPERAZINES;

EID: 33846923855     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-006-0256-2     Document Type: Article

References (16)

1. European Society of Hypertension Guidelines Committee (2003) 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertension 21:1011-1053
2. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ, The National High Blood Pressure Education Program Coordinating Committee (JNC VII) (2003) Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 42:1206-1252
3. Stoschitzky K, Koshucharova G, Zweiker R, Lercher P, Maier R, Watzinger N, Kraxner W, Klein W, Donnerer J (2003) Different effects of propranolol, bisoprolol, carvedilol and doxazosin on heart rate, blood pressure, and plasma concentrations of epinephrine and norepinephrine. J Clin Basic Cardiol 6:69-72
4. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) (2000) Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlortalidone. JAMA 283:1967-1975
5. Dooley M, Goa KL (1998) Urapidil: a reappraisal of its use in the management of hypertension. Drugs 56:929-955
6. Palatini P, Julius S (1997) Heart rate and the cardiovascular risk. J Hypertension 15:3-17
7. Levine HJ (1997) Rest heart rate and life expectancy. J Am Coll Cardiol 30:1104-1106
8. Palatini P, Casiglia E, Julius S, Pessina AC (1999) High heart rate-a risk factor for cardiovascular death in elderly men. Arch Intern Med 159:585-592
9. Palatini P, Thijs L, Staessen JA, Fagard RH, Bulpitt CJ, Clement DL, de Leeuw PW, Jaaskivi M, Leonetti G, Nachev C, O'Brien ET, Parati G, Rodicio JL, Roman E, Sarti C, Tuomilehto J, for the Syst-Eur Trial Investigators (2002) Predictive value of clinic and ambulatory heart rate for mortality in elderly subjects with systolic hypertension. Arch Intern Med 162:2313-2321
10. Jouven X, Empana JP, Schwartz PJ, Desnos M, Courbon D, Ducimetière P (2005) Heart-rate profile during exercise as a predictor of sudden death. New Engl J Med 352:1951-1958
11. Palatini P (2005) Heart rate: a strong predictor of mortality in subjects with coronary artery disease. Eur Heart J 26:943-945
12. Diaz A, Bourassa MG, Guertin MC, Tardif JC (2005) Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 26:967-974
13. Furberg CD, Psaty BM, Meyer JV (1995) Dose-related increase in mortality in patients with coronary heart disease. Circulation 92:1068-1073
14. Pahor M, Guralnick JM, Corti MC, Foley DJ, Carbonin P, Havlik RJ (1995) Long-term survival and use of antihypertensive medications in older persons. J Am Geriatric Soc 43:1191-1197
15. Epstein M (1996) Calcium antagonists: still appropriate as first line antihypertensive agents. Am J Hypertens 9:110-121
16. Furberg CD, Psaty BM (1996) Calcium antagonists: not appropriate as first line antihypertensive agents. Am J Hypertens 9:122-125